Sysmex Corporation (SSMXF)

Market Cap	5.46B -51.2%
Revenue (ttm)	3.21B +0.2%
Net Income	285.40M -22.6%
EPS	0.46 -22.5%
Shares Out	n/a
PE Ratio	19.12
Forward PE	n/a
Dividend	0.25 (2.92%)
Ex-Dividend Date	Mar 30, 2026

Volume	10,441
Average Volume	6,240
Open	8.43
Previous Close	8.33
Day's Range	8.43 - 8.43
52-Week Range	8.33 - 20.40
Beta	0.66
RSI	31.81
Earnings Date	May 8, 2026

About Sysmex

Sysmex Corporation engages in the development, manufacture, and sale of diagnostic instruments, reagents, and related software. It offers non-clinical blood testing and cell analysis for hematology, such as XN-V series, a software for laboratory animal corresponding to XN series fully automated hematology analyzers; XN-Series, a fully automated flagship hematology analyzers; and Automated hematology analyzer ProCyte Dx for Research applications, a housed in a compact body that simultaneously measures five types of leukocytes and reticulocyte co...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1968
• Employees: 10,533
• Stock Exchange: OTCMKTS
• Ticker Symbol: SSMXF

Financial Performance

In fiscal year 2025, Sysmex's revenue was 508.64 billion, an increase of 10.21% compared to the previous year's 461.51 billion. Earnings were 53.67 billion, an increase of 8.12%.

Financial numbers in JPY